Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (REGN)

Statement of Financial Position, Liabilities and Stockholders’ Equity
Quarterly Data

Difficulty: Beginner

The statement of financial position provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Regeneron Pharmaceuticals Inc., Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity (quarterly data)

USD $ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Accounts payable 218,200  172,361  171,906  207,611  178,183  –  –  –  –  –  –  –  –  –  –  –  –  –  –  – 
Accrued expenses and other current liabilities 772,100  781,924  670,709  666,216  637,162  818,760  716,761  1,062,653  880,274  718,502  763,338  746,784  657,675  579,934  531,796  464,947  580,635  339,228  284,445  238,995 
Capital and facility lease obligations, current portion –  –  –  –  –  –  –  7,200  129,557  –  –  –  –  –  –  –  –  –  –  – 
Deferred revenue from Sanofi 246,700  246,812  308,179  231,447  177,746  187,036  184,452  112,161  115,267  105,041  104,141  99,314  101,573  100,908  18,026  19,342  15,927  13,368  12,979  12,980 
Deferred revenue, other 205,800  216,133  180,396  160,466  142,392  132,832  127,804  126,257  116,397  137,642  84,084  73,626  51,914  54,148  51,720  51,845  58,098  57,604  54,154  53,093 
Current liabilities 1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724  811,162  734,990  601,542  536,134  654,660  410,200  351,578  305,068 
Capital and facility lease obligations, excluding current portion 708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230  362,919  364,144  357,687  328,394  310,938  276,112  234,525  203,380 
Deferred revenue from Sanofi 279,300  421,196  339,040  406,778  379,936  408,786  443,904  520,191  503,474  529,791  549,342  565,773  582,664  599,339  46,095  48,656  72,367  75,283  75,862  73,694 
Deferred revenue, other 184,900  197,651  199,401  257,967  249,263  274,666  295,621  316,227  327,298  327,868  146,449  170,658  82,015  78,942  76,748  114,318  103,909  114,339  128,042  128,539 
Convertible senior notes –  –  –  –  –  –  –  –  –  –  –  –  –  30,723  30,360  144,082  146,773  287,950  282,261  326,673 
Other noncurrent liabilities 361,700  194,033  190,020  169,922  152,073  125,225  115,920  106,248  100,385  135,700  119,523  120,993  115,535  77,910  76,080  55,559  40,855  23,747  14,968  11,794 
Noncurrent liabilities 1,534,400  1,520,083  1,434,364  1,539,312  1,484,725  1,510,994  1,556,618  1,643,073  1,282,726  1,375,587  1,176,837  1,219,654  1,143,133  1,151,058  586,970  691,009  674,842  777,431  735,658  744,080 
Total liabilities 2,977,200  2,937,313  2,765,554  2,805,052  2,620,208  2,649,622  2,585,635  2,951,344  2,524,221  2,336,772  2,128,400  2,139,378  1,954,295  1,886,048  1,188,512  1,227,143  1,329,502  1,187,631  1,087,236  1,049,148 
Preferred Stock, $.01 par value; issued and outstanding - none –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  – 
Class A Stock, convertible, $.001 par value –  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2 
Common Stock, $.001 par value 100  110  110  110  110  109  109  108  108  107  107  107  106  106  105  103  102  100  100  99 
Additional paid-in capital 3,911,600  3,841,174  3,712,599  3,611,599  3,512,833  3,570,673  3,449,622  3,190,882  3,029,993  3,314,982  3,156,942  3,049,651  3,099,526  2,880,109  3,118,969  2,812,573  2,404,118  2,423,434  2,342,839  2,236,931 
Retained earnings (accumulated deficit) 5,254,300  4,433,904  3,839,179  3,287,767  2,946,733  2,773,214  2,384,897  1,997,153  1,748,222  1,495,107  1,230,303  1,018,436  852,700  697,706  487,308  292,665  255,382  145,206  65,486  (27,249)
Accumulated other comprehensive income (loss) (12,300) (10,519) (11,612) (15,594) 640  23,835  2,348  (5,884) (12,840) (2,899) 5,204  4,364  8,572  7,721  19,153  47,904  52,251  26,895  4,263  1,465 
Treasury Stock, at cost (396,400) (396,371) (353,852) (316,240) (316,240) (316,240) (316,240) (316,240) (316,240) (316,052) (316,052) (307,478) (306,069) (288,777) (287,079) (181,817) (169,530) (43,849) (43,848) – 
Stockholders’ equity 8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430  2,542,325  2,551,788  2,368,842  2,211,248 
Total liabilities and stockholders’ equity 11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573  3,871,827  3,739,419  3,456,078  3,260,396 

Based on: 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-12), 10-Q (filing date: 2014-11-04), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-08).

Item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.